ArticleJournal of oncology2010
New targeted molecular therapies for dedifferentiated thyroid cancer.
Article in Journal of oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma.Frontiers in endocrinology · 2026Article
- A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.Frontiers in endocrinology · 2023Article
- Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon/rectum, thyroid, and prostate: With a brief literature review.World journal of clinical cases · 2022Article
- Characterization of focal hypermetabolic thyroid incidentaloma: An analysis with F-18 fluorodeoxyglucose positron emission tomography/computed tomography parameters.World journal of clinical cases · 2022Article
- Longitudinal Genomic Evolution of Conventional Papillary Thyroid Cancer With Brain Metastasis.Frontiers in oncology · 2021Article
- Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.Cancer medicine · 2018Article
- Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.Oncotarget · 2017Article
- Article
- New therapies for dedifferentiated papillary thyroid cancer.International journal of molecular sciences · 2015Review
- Molecular Targeted Therapies of Aggressive Thyroid Cancer.Frontiers in endocrinology · 2015Review
- Selective use of vandetanib in the treatment of thyroid cancer.Drug design, development and therapy · 2015Review
- Application of molecular diagnostics to the evaluation of the surgical approach to thyroid cancer.Current genomics · 2014Article
- Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.Current genomics · 2014Article
- RET TKI: potential role in thyroid cancers.Current oncology reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dedifferentiated thyroid cancer (DeTC) derived from follicular epithelium is often incurable because it does not respond to radioiodine, radiotherapy, or chemotherapy. In cases, RET/PTC rearrangements are found in 30%-40%, RAS mutations in about 10%, and BRAF mutations in around 40%-50%, with no overlap between these mutations results in papillary thyroid cancer, while a higher prevalence of BRAF mutations (up to 70%) has been observed in DeTC. The identification of these activating mutations in DeTC makes this malignancy an excellent model to examine the effect of tyrosine kinase inhibitors (TKIs). Clinical trials with several TKIs targeting RET, and to a lesser extent BRAF, and other TKRs have shown positive results, with about one-third of DeTC showing a reduction in tumor size up to 50%, with the longest treatment duration of approximately three-four years. Angiogenesis inhibitors have also shown promising activity in DeTC. Progress is being made toward effective targeted DeTC therapy. The possibility of testing the sensitivity of primary DeTC cells from each subject to different TKIs could increase the effectiveness of the treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.